Author: acn

HONG KONG, Mar 28, 2026 - (ACN Newswire via SeaPRwire.com) - On 27 March, Ausnutria Dairy Corporation Ltd (Stock Code: 1717.HK, hereinafter referred to as "Ausnutria" or the "Company") officially released its 2025 annual results announcement. According to the announcement, Ausnutria achieved revenue of approximately RMB7.488 billion in 2025, representing a year-on-year increase of 1.2%. The Company recorded EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) of approximately RMB518 million. Excluding the impact of one-off non-recurring items, core EBITDA reached approximately RMB616 million, demonstrating the Company's steady progress in navigating industry cycles. In 2025, driven by the dual engines of Family Nutrition and International Business, Ausnutria achieved resilient revenue growth while making significant breakthroughs in product category mix and regional market expansion. Notably, the international business of Kabrita has approached the RMB1 billion mark, with a compound annual growth rate exceeding 50% for three consecutive years, as its new global business ecosystem continues to take shape at an accelerated pace.Over the past year, the global economy has been marked by complexity and volatility, with heightened uncertainties arising from geopolitical tensions, inflation and exchange rate fluctuations. Compounded by intensifying competition amid a contracting domestic infant milk formula (IMF) market, the industry has faced multiple severe challenges. Against this backdrop, Ausnutria has maintained its strategic resolve, deepening its core strengths. The Company's international business has continued to unleash its growth momentum, while the Family Nutrition business has flourished across multiple fronts. Market share in core milk powder categories has steadily increased, and the level of refined management has improved significantly. Through these multi-dimensional efforts to enhance operational resilience, Ausnutria has laid a solid foundation for its long-term development.Kabrita International Business Approaches RMB1 Billion Mark with CAGR Exceeding 50% for Three Consecutive YearsIn 2025, Ausnutria further accelerated its internationalization efforts, continuously strengthening its comprehensive capabilities in global supply chain deployment, localised operations and digital collaboration, driving continued explosive growth in its overseas business. During the reporting period, revenue from the international business of Ausnutria's goat milk formula brand Kabrita recorded a year-on-year increase of 50.7% to approximately RMB974 million, making it the first infant goat milk formula brand from a Chinese dairy company to approach RMB1 billion in overseas sales. With a compound annual growth rate exceeding 50% for three consecutive years, the growing contribution of overseas markets has become increasingly prominent.Revenue from the Middle East market recorded a year-on-year increase of 65.5%, accounting for 45.7% of total overseas revenue and maintaining its position as Ausnutria's largest overseas sales market. Growth in this region was primarily driven by strong performance across established markets including Saudi Arabia, the UAE, Qatar and Kuwait, where the Company strengthened its promotion through medical and healthcare professional channels, continuously enhancing the medical endorsement of its goat milk formula products in these markets. Saudi Arabia delivered a particularly outstanding performance, leveraging deep collaborations with local maternity, infant care and medical institutions to effectively boost consumer acceptance and market penetration. Notably, Kabrita was awarded the "Fastest Growing Brand" accolade by Nahdi, the largest pharmacy retailer in the country. The newly entered Oman market in 2025 also exceeded expectations, injecting fresh momentum into the Company's growth.Revenue from the Commonwealth of Independent States (CIS) market recorded a year-on-year increase of 40.1%, accounting for 23.9% of total overseas revenue. As one of the Company's earliest overseas markets, the CIS market has achieved full product category coverage for Kabrita, encompassing infant formula, cereals, fruit purees, biscuits and more, comprehensively meeting the diverse consumer needs in the region. Through its "360° Omni-channel Marketing" strategy and "DTC Loyalty Program", the Company has engaged target consumers in a distinctive manner, building high value-added brand recognition and continuously consolidating and strengthening its core competitiveness in this market.Revenue from the North American market recorded a year-on-year increase of 39.5%, accounting for 22.2% of total overseas revenue. In 2025, Kabrita successfully entered Walmart, the largest retailer in the United States, and has now expanded into 780 stores, progressively developing both online and offline channels to reach a broader consumer base. In the newly entered Canadian market, the Company has been deepening its presence through the core Walmart channel while gradually building momentum on Amazon.In addition, the Company achieved 100% year-on-year growth in the Southeast Asian market by strengthening product differentiation through formula upgrades, with a particular focus on advancing digital community engagement and deepening collaboration with e-commerce channels and local platforms.Family Nutrition Achieves Steady Growth, Building Multi-dimensional Foundations for Future SuccessAs the Company's continuously nurtured "second growth curve" business, Ausnutria's nutrition products business achieved steady growth in 2025, with revenue recording a year-on-year increase of 5.2%. According to the announcement, this revenue growth was primarily attributable to continuous innovation in star probiotic strains and products, precise execution of channel strategies, and the sustained release of brand equity.Research-driven brand development. Ausnutria entered into a six-year strategic partnership with Jiangnan University, establishing the Joint Innovation Centre for Microecology and Functional Dairy as well as the Collaborative Innovation Centre for Probiotics, embarking on a new chapter of full-chain innovation collaboration. In the B2B segment, the Company achieved several key breakthroughs in probiotic strains: Bifidobacterium longum subsp. infantis YLGB-1496 was approved by the National Health Commission (NHC) for inclusion in the list of edible bacterial strains for infants and young children. With this approval, Ausnutria now possesses two nationally approved infant probiotic strains, earning its distinction as the "double champion" in China's infant probiotics field. Additionally, the independently developed Bifidobacterium animalis subsp. lactis CP-9 obtained the U.S. FDA GRAS (Generally Recognized as Safe) certification, marking Ausnutria's achievement of world-leading standards in research innovation and quality control. The continuous breakthroughs in strain technology provide strong and enduring core momentum for brand development. In the B2C segment in 2025, NC Stomach Care Powder and NC Nasal Comfort Probiotics maintained top rankings in category search popularity on Xiaohongshu. As certified by Euromonitor International, NC was awarded the title of "No.1 in National Sales of Australian Brand Nasal Sensitivity Probiotics".Innovation in response to emerging consumer demands. Bio(R) (Baoyichang(R)) Active Lactic Acid Bacteria Powder introduced a mini space capsule design, setting new aesthetic standards for probiotic products. Yili Changshi Probiotics, formulated with the patented BL-99 strain, achieved a top position on e-commerce bestseller lists. Diversified dosage form solutions, including instant-dissolve powder and micro-effervescent tablets, have effectively enhanced the product competitiveness of business partners. Throughout the year, NC launched 17 new products including G13 Growth Capsules and Sleep Well Probiotics, building a precision nutrition matrix covering gastrointestinal health, nasal sensitivity, sleep, growth, eye and brain health, liver and kidney health, and women's health.Channel upgrades fueling business development. The Company continued to deepen its presence in pharmaceutical channels, achieving simultaneous growth in both scale and pace of expansion. Collaboration with leading platforms was further strengthened, driving rapid growth in private domain e-commerce. The application of star probiotic strains was reinforced, enabling continued expansion of brand clientele. The Company also made breakthroughs in overseas market reach by expanding into European and North American markets. NC achieved steady growth on mainstream e-commerce platforms such as Tmall and JD.com, with the Stomach Care and Nasal Comfort product lines becoming leading brands in the cross-border health supplement category through channels such as Sam's Club and China Duty Free (CDF). The Company partnered with XKA and Fengxiangjia to develop its private domain presence, building an incremental online growth matrix. Offline, the Company consolidated its core client base, expanded into potential customer segments, and achieved initial results from pharmaceutical channel pilot programmes, laying a solid foundation for diversified business development.Domestic Milk Powder Business Steadily Increases Market Share, Solidifying Core FundamentalsChina's infant milk formula (IMF) industry is currently undergoing a period of deep structural adjustment, facing multiple pressures including overall market contraction, intensifying competition, and channel transformation, while birth rate fundamentals and channel structure remain under sustained pressure. During the reporting period, Ausnutria solidified its core fundamentals amid cyclical industry challenges, achieving steady growth in market share for its self-owned milk powder brands and recording overall revenue of approximately RMB5.321 billion.According to NielsenIQ and Syntun data, Kabrita's market share in China's all-channel Goat Milk formula market increased by 2.6 percentage points to 30.2% in 2025. NielsenIQ data further shows that Kabrita has maintained a market share of over 60% in China's imported infant and child goat milk formula market for eight consecutive years (2018–2025). Confirmed by Frost & Sullivan research, Kabrita continues to hold the undisputed position of "No.1 in Global Goat Milk Formula by Both Sales Volume and Sales Value", underscoring its unassailable market leadership.NielsenIQ data also indicates that the Company's cow milk formula business has stabilised its market share, marking the full conclusion of the transitional impact arising from earlier internal integration and channel restructuring. As of the date of this announcement, Ausnutria's Hyproca brand has been awarded dual certifications by iiMedia Research, namely "No.1 in National Sales of Comprehensive Nutrition Infant Formula in 2025" and "Pioneer of Comprehensive Nutrition Infant Formula in China", marking the third consecutive year that Hyproca has topped the comprehensive nutrition formula sales rankings.In 2025, the Company successfully completed the registration of 24 products across 8 series under the New National Standard 2.0 and launched 6 infant formula products across 2 series as well as 25 modulated milk powder products, offering consumers a wider range of functionalised and differentiated product choices. Kabrita was awarded the First Prize for Technological Advancement at the Science and Technology Awards for its research and development project titled "Research and Development of an Infant Formula that Supports Immune Regulation and Alleviates Immune Stress". Meanwhile, Hyproca 1897 was recognized as a "100% Quality Product", with the Company's product strength receiving authoritative endorsement.Lean Management Enhances Quality and Efficiency, Organizational Vitality Continues to FlourishIn 2025, Ausnutria continued to solidify the foundation for long-term development and achieve simultaneous improvements in organizational efficiency and development quality through a series of initiatives, including fully leveraging the momentum of its global supply chain, strengthening internal management effectiveness, establishing the cultural foundation for global collaboration, advancing the construction of its digital intelligence system, and enhancing its sustainable development governance capabilities.Global supply chain momentum unlocks new value growth opportunities. Following Ausnutria's acquisition of Amalthea Group, a Dutch goat cheese company, the Company achieved self-sufficiency in goat whey, a core ingredient for goat milk formula, while also adding cheese to its product portfolio. In 2025, the Company's Goat Cheese business recorded revenue of RMB1.006 billion, further deepening the moat of its internationalization strategy. Concurrently, the Company launched four major goat-based ingredients: goat cheese protein hydrolysate, hydrolyzed goat whey protein powder, goat lactoferrin, and goat colostrum powder. Several of these core goat milk ingredients achieved breakthroughs in commercially viable global applications from scratch, opening up new avenues for value creation for the Company.Internal management effectiveness strengthened to systematically drive sound operations. In 2025, the Company's inventory impairment provisions decreased by 0.9 percentage points year-on-year. Overall asset turnover ratio continued to improve, with inventory turnover days declining by 16 days. The Company continued to advance refined cost management, achieving a notable optimization in its expense ratio, which decreased by 1.4 percentage points year-on-year, with the selling and marketing expense ratio declining by 2.4 percentage points year-on-year.Global systematization of business philosophy to strengthen global strategic synergy. To better align with the pace of business development and reinforce Ausnutria's "one global chessboard" strategic approach, the Company officially released the "Ausnutria Business Philosophy (Overseas Edition)". Co-created through multiple rounds of in-depth discussions among over 60 core managers from Ausnutria's global operations, this business philosophy systematically establishes the core values and management principles for Ausnutria's overseas business. It serves as a tailor-made cultural compass and behavioral benchmark for overseas teams, laying a solid ideological foundation for future business development.Full-chain digital intelligence upgrade, empowering both business and management. The Company has introduced digital intelligence across all stages, from demand research and process design to implementation and execution, enabling traceable decision-making, monitorable processes and quantifiable results. Through the establishment of a data middle platform, intelligent analytical models and other tools, data has become the core enabler for optimising management and supporting business operations, fundamentally safeguarding the sustained and healthy development of the business.Upholding sustainable development principles and actively fulfilling corporate social responsibility. The Company has always adhered to a long-term vision for sustainable development, actively responding to the United Nations Sustainable Development Goals. Centred on three strategic pillars "Better Life, Better Nutrition, Better Environment” the Company has embedded sustainability principles into its operational management framework and across all stages of the value chain. In 2025, Ausnutria organized the "Hyproca Gesang Flower Charity Campaign" for the ninth consecutive year and launched the "Kabrita Care · Worry-free Pregnancy" maternal mental health charity initiative, among other activities. The Company has continued to contribute its corporate strengths in areas such as rural revitalization, education support, national nutrition enhancement and natural disaster relief.In 2025, with the support of consumers, shareholders and all sectors of society worldwide, together with the dedicated efforts of all employees, the Company successfully navigated the multiple challenges arising from economic and industry cyclical adjustments. Looking ahead to 2026, the internal and external environment remains complex and challenging. Ausnutria will continue to put consumers at the center, stay anchored to its operational objectives, accelerate systematic organizational development, drive growth through innovation, enhance efficiency through management excellence, and deliver superior products and performance to reward the trust of all stakeholders, in pursuit of long-term sustainable and high-quality development. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月28日 - (亚太商讯 via SeaPRwire.com) - 3月27日，澳优乳业股份有限公司（股份代号：1717.HK，以下简称"澳优"或"公司"）正式发布2025全年业绩公告。公告显示：2025年，澳优实现营业收入约人民币74.88亿元，同比增长1.2%；实现EBITDA（息税折旧及摊销前利润）约人民币5.18亿元；剔除一次性非经常性项目的影响，实现核心EBITDA约人民币6.16亿元，以稳健的步伐穿越行业周期。2025年，澳优通过全家营养与国际业务的双轮驱动，实现营收韧性增长，并在品类结构与区域市场拓展上取得突破。其中，佳贝艾特国际业务规模已接近10亿元，连续三年复合增长率超过50%，全球业务新生态正加速成型。过去一年，全球经济复杂多变，地缘政治、通胀及汇率波动等不确定性加剧，叠加国内婴配粉市场减量竞争日趋激烈，行业面临多重严峻挑战。在此背景下，澳优始终保持战略定力，深耕核心优势，国际业务势能持续释放，全家营养业务多点开花，奶粉核心品类市占率稳步提升，精细化管理水平显著提高，从多维度提升经营韧性，筑牢公司长远发展根基。佳贝艾特国际业务接近10亿规模，连续三年复合增长率超50%2025年，澳优进一步加快国际化步伐，不断增强全球供应链布局、本地化运营、数字化协同等综合硬实力，驱动海外业务继续取得爆发式增长。公告期内，澳优羊奶粉佳贝艾特（Kabrita）国际业务收入实现同比增长50.7%至约人民币9.74亿元，成为中国乳企第一个在海外市场销售额接近10亿规模的婴配羊奶粉品牌，连续三年复合增长率超50%，海外市场的增长贡献持续凸显。中东市场营收同比增长65.5%，占海外总营收45.7%，保持澳优海外最大销售市场的地位。该区域增长主要得益于沙特、阿联酋、卡塔尔、科威特等成熟市场全面开花，通过强化医疗专业渠道推广，持续提升公司羊奶粉在这些市场的医学认可度。其中沙特市场表现亮眼，依托与当地母婴及医疗机构的深度合作，有效提升消费者接受度与市场渗透率，并斩获当地最大的药房零售商Nahdi"增长最快品牌" 荣誉。2025年新开拓的阿曼市场表现超预期，为增长注入新动能。独联体市场营收同比增长40.1%，占海外总营收23.9%。作为公司首批布局的海外市场，独联体市场已实现佳贝艾特全品类覆盖，包含婴幼儿配方奶粉、谷物、果泥、饼干等，充分满足当地多元消费需求。通过"360°全域营销"与"DTC忠诚计划"以独特方式触达目标人群，构建高附加值品牌认知，实现公司在该市场的核心竞争力持续巩固与提升。北美市场营收同比增长39.5%，占海外总营收22.2%。2025年，佳贝艾特成功进驻美国最大零售商沃尔玛，目前已进入780家门店，有序拓展线上及线下渠道，覆盖更广泛消费群体。新进入的加拿大市场，深耕核心沃尔玛渠道，并在亚马逊渐进发力。此外，公司在东南亚市场通过配方升级以强化产品差异化，重点推进数字化社群运营，深化电商渠道与本地平台合作，实现了100%增长。全家营养稳步增长，多维筑基蓄力远航作为持续培育的"第二增长曲线"业务，2025年澳优营养品业务稳步增长，录得收入同比增长5.2%。公告显示，收入的增长主要得益于明星菌株和产品的不断创新、渠道策略的精准实施以及品牌效应的持续释放。科研驱动品牌发展。澳优与江南大学签订六年战略合作，成立微生态及功能乳联合创新中心和益生菌协同创新中心，开启全链路创新协同新征程。To B 业务板块，公司在菌株上实现多项关键突破：长双歧杆菌婴儿亚种 YLGB-1496 获国家卫健委批准列入婴幼儿可食用菌种名单，至此澳优已拥有两株国家批准的婴幼儿益生菌菌株，成为中国婴幼儿益生菌领域的"双冠王"；自主研发的动物双歧杆菌乳亚种 CP-9 通过美国 FDA GRAS 认证，标志着澳优在科研创新和质量管控方面达到世界领先水平。菌株技术的持续突破，为品牌发展提供强劲持久的核心动能。2025年，To C业务板块，NC养胃粉、舒鼻益生菌稳居小红书品类搜索热度前列；经欧睿国际认证，NC荣获 "澳洲品牌鼻敏益生菌全国销量第一"。创新响应新消费需求。葆益常(R)活性乳酸菌粉以迷你太空舱设计解锁益生菌产品颜值新高度；添加BL-99 专利菌株的伊利畅适益生菌跻身电商热销榜；闪溶粉、微泡片等多元剂型方案，有效提升合作伙伴产品竞争力。NC全年推出G13成长胶囊、恬睡益生菌等17款新品，构建起覆盖肠胃、鼻敏、睡眠、身高、眼脑、肝肾及女性健康等领域的精准营养矩阵。渠道升级助力业务发展。公司持续深耕药线渠道，规模与增速同步提升；深化头部平台合作，私域电商高速增长；强化明星菌株应用，品牌客户持续拓展；开拓欧美市场，海外市场空间实现突破。NC在天猫、京东等主流电商稳健增长，养胃、舒鼻系列产品在山姆、中免等渠道成为跨境保健品类目领先品牌；携手XKA、蜂享家布局私域，构建线上增量矩阵；线下稳固核心客户、拓展潜力客群，药线试点初见成效，为业务多元发展夯实基础。国内奶粉业务市占率稳步提升，筑牢核心基本盘当前中国婴配粉行业处于深度调整期，面临总量收缩、竞争加剧、渠道变革等多重压力，新生人口基本面与渠道结构持续承压。公告期内，澳优在行业周期性挑战中筑牢核心基本盘，实现自有品牌奶粉业务市占率稳步提升，录得整体收入约人民币53.21亿元。据尼尔森IQ及星图数据，2025年佳贝艾特在中国全渠道羊奶粉市场份额提升2.6个百分点至30.2%。尼尔森IQ数据显示，佳贝艾特已连续8年（2018年-2025年）在中国进口婴幼童羊奶粉市场份额超六成，并经过弗若斯特沙利文研究确认持续稳居"羊奶粉全球销量与销售额第一"，彰显其不可撼动的领头羊地位。尼尔森IQ数据同时显示，公司牛奶粉业务稳住市场份额，标志着因前期内部整合与渠道调整带来的阶段性影响全面结束。截至公告发布期，澳优旗下海普诺凯斩获艾媒咨询（iiMedia Research）"2025婴幼儿全面营养奶粉全国销量第一"及"中国全面营养婴配奶粉开创者"双重认证，这也是其连续三年蝉联全面营养奶粉销量榜首。2025年，公司顺利推进8个系列24款产品新国标2.0注册，完成2个系列6款婴幼儿配方奶粉、25款调制乳粉开发上市，为消费者提供更多功能化、细分化的产品新选择。佳贝艾特凭借《一种有助于免疫调节和缓解免疫应激的婴幼儿配方奶粉的研究与开发》荣获"科学技术奖技术进步奖"一等奖，海普诺凯1897获评"质量百分百产品"，产品力获权威认可。精益管理提质增效，组织活力持续迸发2025 年，澳优通过充分释放全球供应链势能、强化内部管理效能、塑造全球协同文化根基、推进数智化体系建设、提升可持续发展治理能力等举措，持续夯实长远发展基础，不断实现组织效率与发展质量的同步提升。全球供应链势能释放，开辟价值增长空间。澳优收购荷兰羊奶酪公司Amalthea Group后，实现核心羊奶粉原料——羊乳清自给自足，并新增奶酪品类。2025年，公司羊奶酪业务录得收入10.06亿元，进一步挖深国际化战略护城河。与此同时，公司推出羊奶酪蛋白酶解物、水解羊乳清蛋白粉、羊乳铁蛋白以及羊初乳粉四大羊原料，其中多款核心羊乳原料实现了全球可商业化应用从无到有的突破，为公司开辟全新的价值增长空间。内部管理效能强化，系统推进稳健经营。2025年，公司存货减值准备同比减少0.9个百分点；整体资产周转率持续优化改善，存货周转天数下降16天。公司持续推进费用精细化管控，费用率实现显著优化，同比下降1.4个百分点，其中营销费用率同比下降2.4个百分点经营理念全球体系化构建，加强全球战略协同。为更好地匹配业务发展步伐，强化澳优"全球一盘棋"的战略协同，澳优正式发布《澳优经营理念（海外版）》。该经营理念由澳优全球60余位核心管理者通过多轮深度研讨共创而成，系统构建了澳优海外业务的核心价值与管理原则，为海外团队量身打造了文化罗盘与行为基准，为未来业务发展奠定了坚实的思想根基。全链路数智化升级，为业务与管理双向赋能。公司从需求调研、流程设计到落地执行的全环节引入数智化，实现决策可追溯、过程可监控、结果可量化；通过搭建数据中台、智能分析模型等工具，让数据成为优化管理、支撑业务的核心抓手，从根本上保障业务的持续健康发展。秉持可持续发展理念，积极践行企业社会责任。公司始终秉持可持续发展的长期愿景，积极响应联合国可持续发展目标，围绕"更优生活、更优营养、更优环境"三大战略支点，将可持续发展理念融入运营管理体系及价值链各环节。2025年，澳优连续第九年开展"海普诺凯格桑花公益行"、启动"佳贝爱・孕无忧"孕产妇心理健康公益行等活动，持续在乡村振兴、兴教助学、国民营养提升、自然灾害救助等方面持续贡献企业力量。2025年，依托全球消费者、股东、社会各界的支持及全体员工的奋力拼搏，公司成功抵御经济及行业周期性调整带来的多重挑战。展望 2026年，内外部环境依然复杂严峻，澳优将继续以消费者为中心，锚定经营目标，加快体系化建设，以创新驱动发展，以管理提升效能，以更优质的产品与业绩回馈各方信赖，实现长期可持续高质量发展。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亚太商讯 via SeaPRwire.com) - 随着人工智能加速迈向推理阶段，企业级AI迎来规模化落地，Token消耗呈指数级攀升，数据需求进入全新发展阶段。在这一趋势下，高质量、结构化、场景化的专业数据，正成为AI时代企业构建核心战略竞争能力的关键所在。作为中国领先的AI实时数据基础设施及分析服务商，迅策科技得益于赛道红利，凭借全链路技术能力与多元增长引擎驱动，正加速确立其在AI数据层的核心地位。随着智能经济新形态的全面展开，这家深耕十年的企业正迎来结构性价值重估的窗口期。Token价值重构：让每一次数据调用都可量化、可计价迅策科技成立于2016年，历经十年发展，已构建起覆盖数据获取、清洗、标准化、实时计算至大模型调优的全链路技术体系。公司以AI Data Agent为核心，专注于毫秒级实时数据处理，服务领域涵盖金融、城市运营、高端制造、医疗、机器人、卫星、低空经济、电力、电网及能源等多元化产业。在AI推理时代开启的当下，Token正从"燃料"进化为"硬通货"。如何将每一个Token的价值最大化，成为大模型推理阶段的核心命题。当前，通用大模型普遍采用"用算力换精度"的策略，每一次推理都伴随着大量无效Token消耗。一旦推理失败，前期投入的Token全部作废——这是通用AI面临的共同困境。相比之下，垂类AI解决方案则是用行业数据为通用大模型安装一个"外脑"。其核心在于用业务模型优化推理路径，提前判断任务可行性，从源头避免Token浪费。长期深耕专业垂类数据建模领域的迅策科技，凭借其多年积累的高质量、场景化垂类数据，相当于为每一次Token调用加装了"增效器"，在消耗 Token 时换取更高精度的结果，实现最高的产出确定性。更为关键的是，公司正在构建全链路的数据计量、计费、结算能力，使每一次数据调用，都可量化、可计价，通过提升每单位Token的有效性，为客户带来更高的业务价值。围绕这一思路，迅策科技的平台采用"乐高式"模块化架构，让客户可以根据自身需求灵活组合模块，实现"按需装配、随需而变"，建立深度黏性。公司在定价与收费模式上亦遵循灵活设定，基于模块数量、处理速度等维度，销售采用订阅制、交易制以及按Token收费制的模式，以精准匹配客户需求。目前，迅策科技正全力构建全链路的数据计量与结算体系，探索按大模型调用次数与模块应用个数等维度计价，让客户为"有效Token"付费，而不是为算力消耗买单。业绩拐点已现，盈利能力得到验证在Token价值重构背景与商业模式创新的推动下，迅策科技业绩表现强劲，迎来历史性拐点：2025年下半年，公司实现经调整净利润0.5亿元，首次实现半年度正向盈利。此外，公司在2025年上半年实现营收1.98百万元，下半年营收跃升至10.87百万元，环比激增449%。公司在高速扩张的同时，盈利能力已开始实质性释放。全年来看，公司实现营业收入达1,284.66亿元，较上年同期大幅增长103.28%，成功跨越"十亿营收"这一关键门槛，标志着公司已从早期技术驱动的初创阶段，正式迈入可规模化复制的平台化发展新纪元。此外，2025年公司综合毛利约为人民币792.08百万元，较上年度约人民币484.63百万元大幅增加63.44%。经调整净亏损方面，扣除一次性非经常性损益后，公司2025年度经调整净亏损为人民币54.84百万元，较2024年度的82.37百万元大幅收窄33%。值得注意的是，2025年公司综合毛利率达62%，不仅高于以AI芯片为核心业务的寒武纪（55%），更远超通用大模型公司Minimax（25.4%），体现出其在AI数据基础设施领域独特的高价值卡位与商业模式韧性。在研发投入方面，迅策科技亦保持了高效的增长转化。2025年公司研发开支达450.44百万元，研发支出占收入比重为48%，驱动营业收入实现105%的同比增长；相比之下，Minimax研发支出占比高达219%，收入增幅为159%。迅策以更低的研发强度，实现了接近同等级别的扩张速度。随着收入规模持续扩大、新行业毛利逐步收敛，公司短期盈利目标为实现经调整净利润迎来拐点。未来随着已投入行业陆续进入毛利收敛期，以及Token付费与分成模式加速落地，公司净利率有望加速提升。多元增长引擎驱动，业务结构持续优化业绩的强劲增长并非偶然，背后是迅策科技多维驱动、系统推进的增长逻辑。加速跨行业复制。公司目前覆盖9大行业，对标Palantir的17个行业，横向拓展空间广阔。迅策科技正加速向资管、电信、电力、城市管理、高端制造、医疗、能源、机器人训练平台、商业航天等国家重点发展的行业纵深拓展。每进入一个新行业，公司先用3-5年完成行业数据沉淀，随后便可实现同行业客户的快速复制推广。商业模式驱动客户价值深耕。 随着客户从单一模块走向多模块部署、从局部试用走向核心业务流程嵌入，ARPU值仍有显著提升空间。通过Token调用次数、模块应用数量及单次Token价值的协同提升，公司将打开全新的增长空间。稳步开拓海外业务，构建全球化布局。公司规划2026年海外收入占比提升至10-15%，2027-2028年持续提升全球化战略，为长期增长开辟新的空间。构建战略合作生态，与算力及算法上下游深度绑定。迅策科技正与国内头部GPU厂商及大模型公司深度合作，构建"底层算力+上层应用+数据治理"的一站式解决方案，进一步巩固其在AI数据层的核心地位。开拓前沿应用，抢占未来产业制高点。从机器人数据平台到商业航天、低空经济、电力电网，迅策科技率先将AI基础设施延伸至对实时性、可靠性要求极高的新兴领域，这些对数据实时性、可靠性要求极致的场景，正是公司技术优势的最佳试金石。公司将持续加大在前沿领域的研发投入，以尖端场景锤炼技术能力，为未来发展开辟高增长、高价值的新赛道。从数据服务商到AI经济核心基础设施，构建深厚竞争壁垒宏观层面来看，人工智能数据领域正迎来五大趋势的深度交汇：AI Agent时代对实时、安全、高质量数据的需求爆发；垂类模型崛起使专业数据成为行业智能化升级的关键要素；Open Claw等新一代AI操作系统将数据接口标准化，迅策科技正成为核心数据Token供应商；Token化付费成为数据要素市场的新范式；数据资产入表政策落地，企业对数据治理的刚性投入需求激增。在这五大趋势的交汇点上，迅策科技逐步构筑起长期发展的坚实底层逻辑。迅策科技不再只是数据基础设施提供商，而是连接模型、算力、云厂商的"连接器"与"赋能者"。向上连接模型，向下连接算力，横向协同云厂商，最终为客户提供不可替代的数据价值。公司强调，其与通用大模型公司是天然的上下游合作关系，而非竞争关系。正如GPU厂商与模型公司深度合作一样，迅策科技的价值在于：客户使用的模型越多，公司的服务机会越多，为客户创造的价值也越多。值得关注的是，与市场上仅做数据清洗、或仅做计算引擎的单一模块厂商不同，迅策科技的核心差异在于全流程覆盖与为结果负责的能力。从数据获取、清洗、标准化、建模、实时计算，到模型调优，提供端到端解决方案，确保最终输出给客户的数据是干净的、准确的、实时的、可被模型秒级调用的。同时，公司深度嵌入客户的私有云或本地系统，扮演"数据管家"角色，形成极高的客户粘性与竞争壁垒。目前，公司产品与解决方案拥有超过300多个功能模块，覆盖从数据基础设施到上层分析的全场景。2025年，公司的付费客户活跃量达到230家，客户留存率高达90%。ARPU值从2024年的272万元，再大幅提升2025年559万元，同比增幅超过103%。当算法走向开源，算力趋于标准化，真正拉开差距的，是数据——尤其是经过深度治理、能够驱动大模型的行业数据。迅策科技凭借十年深耕，已在这一领域构建起深厚的护城河。结语从早期私募工具到跨行业的AI数据基建，从"模块供应商"到"Token计价平台"，迅策科技始终致力于让数据成为真正可流动、被调用、可驱动决策的稀缺资源。在智能经济新形态加速到来的今天，这家公司正站在结构性重估的起点上, 或进入千亿市值阵营。它不是任何人的竞争者，而是所有人都需要的合作伙伴。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com